Free Trial
OTCMKTS:BIOQ

Bioqual Q3 2026 Earnings Results & Report

Bioqual logo
$31.00 0.00 (0.00%)
As of 11/12/2026

Bioqual reported Q3 2026 earnings on April 21, 2026. The company reported EPS of -$0.84, while revenue was $9.84 million.

Earnings Announcement Details

Quarter
Q3 2026
Report Date
Time
Before Market Opens

Bioqual EPS Results

Actual EPS
-$0.84
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Bioqual Revenue Results

Actual Revenue
$9.84 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Bioqual Q3 2026 Earnings FAQ

Bioqual (OTCMKTS:BIOQ) reported earnings of -$0.84 per share for Q3 2026. The report was announced on Tuesday, April 21, 2026.

Bioqual reported revenue of $9.84 million for Q3 2026.

Bioqual Earnings Headlines

My next big call (under $1)
17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community before the big move happened. Now, I'm making my next big call. It's a coin under $1.00 that most investors have never heard of. But the world's largest bank is already building on it. It has a deflationary burn mechanism tied directly to institutional usage. With Bitcoin well off its highs and fear still hanging over the market, this is the exact environment where my biggest winners have been found.tc pixel
BIOQUAL Presents Financial Results for Fiscal Year 2026
See More Bioqual Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bioqual? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bioqual and other key companies, straight to your email.

About Bioqual

Bioqual (OTCMKTS:BIOQ), Inc. is a biomedical research and contract research organization based in the United States. The company provides preclinical research services to pharmaceutical and biotechnology companies, government agencies, and other organizations developing medical treatments, vaccines, and diagnostics.

Its activities include animal-model research, pharmacology, toxicology, infectious-disease studies, and vaccine and therapeutic efficacy testing. Bioqual has experience conducting research involving nonhuman primates and other laboratory animals, supporting the evaluation of potential products before they advance to human clinical trials.

The company’s services are designed to help clients assess safety, effectiveness, and biological responses across a range of medical and public-health applications. Publicly available information about Bioqual’s current leadership, geographic reach, and additional operating details is limited.

View Bioqual Profile